Potential Breakthroughs in Neurotherapeutics: Alzheimer’s Disease, Parkinson’s Disease, Depression, Bipolar Disorder, and Schizophrenia

Title	Published	Price
Snapshots US Pharmaceuticals 2009 By: Snapdata International Group Snapdata's Snapshots US Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the US pharmaceutical market and \| more... Search inside this report	11/12/2009	$600.00
Prostate Cancer Drug Discoveries: What the Future Holds By: Espicom Healthcare Intelligence Prostate cancer is the second leading cause of cancer in the US and the third most common cancer worldwide. More than two million men in the US suffer with prostate cancer. Find out more about \| more... Search inside this report	11/5/2009	$2,460.00
Dealmaking and Industry Outlook: Neurological Disease By: Decision Resources The plethora of recent reports of new genes and pathways linked to neurological diseases shows that the underlying causes of these diseases are far from certain; as a result, therapeutic strategies in effect today may \| more...	11/2/2009	$2,250.00
BI for Drug Development: Oracle Introduces Clinical Development Analytics By: IDC This IDC Health Insights Perspective highlights the announcement of a dedicated life science business intelligence (BI) solution introduced recently at Oracle OpenWorld 2009 that promises to deliver actionable insights into clinical development processes. Oracle Clinical \| more... Search inside this report	11/1/2009	$1,500.00
Pharmaceuticals Industry Report By: Plimsoll Publishing Ltd. The Global Pharmaceuticals Industry Report Plimsoll Publishing Ltd. Do you know.... The top 7 best trading partners in the industry? Which company has the highest sales growth? Which companies have the highest levels of debt? This report is an in-depth financial \| more...	11/1/2009	$1,500.00
Protein Kinase Therapeutics in Oncology - Where to Commercialize? By: BioSeeker Group AB This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of \| more...	10/29/2009	$3,500.00
CDK Inhibitors Patent Landscape 2009 By: France Innovation Scientifique et Transfer IP Overview presents a patent landscape analysis of the CDK Inhibitor field. Alterations in CDK activity have been associated in the development of viral infections, neurodegenerative dis orders such as Alzheimer’s disease and proliferative \| more... Search inside this report	10/29/2009	$1,645.00
Commercial Insight: Antipsychotics - Revenues of depots and new agents will partially offset generic erosion By: Datamonitor Introduction In 2008, seven major market sales of antipsychotics reached $18.2 billion. Datamonitor forecasts the market value to peak in 2011 when it will then succumb to generic erosion, particularly in the US where incursion is \| more...	10/28/2009	$15,200.00
Antipsychotics Market Forecast By: Datamonitor Introduction In 2008, seven major market sales of antipsychotics reached $18.2 billion. Datamonitor forecasts the market value to peak in 2011 when it will then succumb to generic erosion, particularly in the US where incursion is \| more...	10/28/2009	$15,200.00
Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes By: Datamonitor Introduction Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest \| more...	10/20/2009	$5,700.00

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/23/2009 - 2